New Treatments Bring New Challenges: Can You Identify and Mitigate Therapy-related Adverse Events Associated with the Use of Immuno-oncology/Tyrosine Kinase Inhibitor Combination Therapies?

New Treatments Bring New Challenges: Can You Identify and Mitigate Therapy-related Adverse Events Associated with the Use of Immuno-oncology/Tyrosine Kinase Inhibitor Combination Therapies? is organized by Med Learning Group.

Learning Objectives:
• Interpret data from studies exploring the safety/toxicity profiles of IO/TKI combination therapies used to treat patients with advanced solid tumors
• Develop strategies to manage the irAEs and trAEs associated with IO/TKI combination therapies used for the treatment of patients with advanced solid tumors
• Support multidisciplinary team approaches for the diagnosis and management of irAEs in patients with advanced solid tumors treated with combination IO/TKI therapies

Additional details will be posted as soon as information is available.